ClinicalTrials.gg
Active, not recruitingNCT05808699Updated Oct 22, 2024

Camera Qualification Study

An observational study in Diabetic Retinopathy, sponsored by Digital Diagnostics, Inc.. Active, not recruiting at 9 sites in United States. Open to participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2024-10-22.

Sponsored by Digital Diagnostics, Inc. · Observational

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
626
Ages
22 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 267 studies in Diabetic Retinopathy with a site in United States — 36 open to participants now, 55 under way, 6 of them phase 3. Diabetic Retinopathy · United States.

Enrollment
17th of 70
626 · median 161
Started
2023
with 11 others
Observational
70 of 267
8 open now
Primary completion
2023-11
later than 1 of 53 live
Registered
218th of 267
by date
Lead sponsor
4 of 267
Digital Diagnostics, Inc.

Among the 267 studies in Diabetic Retinopathy with a site in United States, this one is the 17th largest by enrollment of the 70 observational ones that give a count, is one of 12 that started in 2023, is one of 70 observational ones, reaches primary completion later than 1 of the 53 other live ones, and was the 218th registered.

Diabetic Retinopathy

779 studies on the registry are indexed under Diabetic Retinopathy; 143 are open to participants now.

Browse Diabetic Retinopathy studies →

Open to participants now

36 of the 267 studies in Diabetic Retinopathy with a site in United States are open now. Recruiting first, the newest first:

31 more — sign in →

All 36 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 92 Diabetic Retinopathy studies recruiting now, 60 (65%) set no upper age limit and 10 (11%) stop at 75 or younger; 8 take children under 18; 29 take healthy volunteers.

This study: 22 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 267 studies in Diabetic Retinopathy with a site in United States, or all of them as a file.
02

Study summary

A multi-center study to evaluate the performance of an automated device for the detection of diabetic retinopathy with the use of an additional fundus camera with IDx-DR.

Read the detailed description

A multi-center Study to demonstrate non-inferiority of the automated device detecting diabetic retinopathy using a handheld fundus camera with IDx-DR.

03

Conditions studied

  • Diabetic Retinopathy

Browse trials for

04

Who can participate

Ages eligible
22 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Primary care clinic - sampling method: non-probability sequential, invitation to volunteer

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 22 years of age or older
  2. Documented diagnosis of diabetes mellitus, as per any of the following:

    1. Having met the criteria established by either the World Health Organization (WHO) or the American Diabetes Association (ADA)
    2. (HbA1c) ≥ 6.5%
    3. Fasting Plasma Glucose (FPG) ≥ 126 mg/dL (7.0 mmol/L)
    4. Oral Glucose Tolerance Test (OGTT) with two-hour plasma glucose (2-hr PG) ≥ 200 mg/dL (11.1 mmol/L), using the equivalent of an oral 75 g anhydrous glucose dose dissolved in water
    5. Symptoms of hyperglycemia or hyperglycemic crisis with a random plasma glucose (RPG) ≥ 200 mg/dL (11.1 mmol/L)
  3. Ability to understand and the willingness to sign a written document

Exclusion criteria

Exclusion Criteria:

  1. Currently participating in an interventional eye study
  2. Has a known allergy to or for the use of Tropicamide 1% or other mydriatic eye drops
  3. Has a condition that, in the opinion of a licensed clinical team member or investigator, would preclude participation in the study (e.g., unstable medical status including blood pressure or glycemic control, microphthalmia or previous enucleation)
  4. Pregnancy
  5. Self-report of visual symptoms including vision loss or blurred vision that cannot be corrected (e.g., with eyeglasses) or floaters
  6. History of laser treatment of the retina, injections into either eye, or any history of retinal surgery
  7. Previous confirmed diagnosis of a retinal disease (e.g., macular edema, severe non-proliferative retinopathy, proliferative retinopathy, radiation retinopathy, or retinal vein occlusion)
  8. Any condition that is contraindicated for the use of the study camera
  9. Contraindication for imaging by devices used in the study due to any of the following:

    1. Subject is hypersensitive to light
    2. Subject recently underwent photodynamic therapy (PDT)
    3. Subject is taking medication that causes photosensitivity
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
626 participants (actual)
Patient registry
No

Groups and cohorts

  • Fundus camera image

    Subjects imaged with a fundus camera

    Device: handheld fundus camera

Interventions

  • Devicehandheld fundus camera

    Fundus camera

06

What researchers measure

Primary outcomes

  1. Sensitivity and Specificity Corrected for Enrichment

    Estimation sensitivity and specificity corrected for enrichment using logistic regression, Level 1

    Time frame: Day 1

Secondary outcomes

  1. Observed Sensitivity and Specificity, Level II

    Estimation diagnosability, and observed sensitivity and specificity

    Time frame: Day 1

Other outcomes

  1. Precision substudy

    Evaluate the repeatability and reproducibility of IDx-DR with the camera in protocol DXSDR006. Additionally, another IRB-approved R\&R study (i.e., similar to DXSDR006 precision substudy) was conducted to evaluate parameters that may optimize R\&R outcomes.

    Time frame: ~1-month after Day 1

07

Study locations

9 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2023 to primary completion in Nov 2023, 8 months.

Of 90 observational studies under Diabetic Retinopathy, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 61. This study's 8 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 29, 2023
First posted
Apr 11, 2023
StartActual
Mar 3, 2023
Primary completionActual
Nov 30, 2023
CompletionEst.
Jan 30, 2025
Last update
Oct 22, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 22, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05808699
Lead sponsor
Digital Diagnostics, Inc.
Collaborators
Laboratory Corporation of America
Responsible party
Sponsor
First posted
Apr 11, 2023
Start date
Mar 3, 2023
Primary completion
Nov 30, 2023
Completion
Jan 30, 2025 (estimated)
Last update
Oct 22, 2024

Study contacts

Michael Abramnoff, MD, PhD
study chair · Digital Diagnostics, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion